After carrying out weeks of Solidarity trials with Hydroxychloroquine, WHO has now suspended the tests temporarily around the world.
The decision comes as a precaution in light of a study - published in The Lancet - that said the drug has no benefit in treating COVID-19 patients and might even increase the risk of dying for those who are critically ill due to it.
Study assessing drug's efficacy on thousands of patients
In The Lancet study, nearly 15,000 of 96,000 coronavirus patients were given Hydroxychloroquine or a related form of chloroquine alone or with an antibiotic. The rest of the patients were given different therapy.
The results of the work revealed that the people in the group taking Hydroxychloroquine were far more likely to die and develop heart rhythm complications than those in the other group.
"It's important to continue to gather evidence on the efficacy and safety of Hydroxychloroquine," WHO Chief Scientist Soumya Swaminathan said at a press briefing. "We want to use it if it's safe and efficacious, reduces mortality, reduces the length of hospitalization without increasing adverse events."
Trump, who has tested negative for COVID-19 at least twice, has been pushing the drug, even calling it a 'game-changer', despite the warnings from public health officials that it could cause heart ailments.
So far, no clinical study has recommended the drug for COVID-19 treatment.